Although dihydrofolate reductase (DHFR) gene amplification is a common mechanism of resistance to methotrexate (MTX) in tumor cell lines, with the exception of a few case reports, the incidence of this phenomenon as a mechanism of MTX resistance in the clinic has not been reported. We studied 38 untreated patients and 29 patients in relapse with acute lymphoblastic leukemia (ALL) for gene amplification and p53 gene mutations. Three patients were studied both at diagnosis and at each of two relapses after treatment with MTX. Nine of 29 relapsed patients (31%) had low-level EVELOPMENT OF resistance to methotrexate (MTX) occurs frequently in cancer patients.' Despite the importance of MTX resistance, relatively little is known of the mechanisms underlying resistance to MTX in the clinic. MTX is a key drug in the curative regimens for acute lymphoblastic leukemia (ALL) and is extensively used for maintenance therapy. However, despite a 90% to 100% complete remission rate, most centers still report relapses in 30% to 40% of patients, and, thus, ALL is an ideal disease in which to examine the mechanisms of acquired MTX resistance? Phenotypic and genetic alterations associated with resistance to MTX have been extensively studied in experimental systems. These have included both quantitative and qualitative alterations at the level of membrane transport, intracellular polyglutamylation, and the primary intracellular target, dihydrofolate reductase MTX is a tight-binding inhibitor of the enzyme DHFR, and the concentration of MTX required to achieve inhibition of enzyme activity increases in direct proportion to the amount of the enzyme in the target cells!.' It is now well established that an important mechanism of resistance of cells to MTX is an increase in DHFR activity due to amplification of the DHFR gene. Mouse, hamster, and human MTXresistant cell lines have been described with increased levels of DHFR activity due to gene amplification.*-" After reports indicating that gene amplification is a common mechanism of resistance in cell lines exposed to gradually increasing doses of MTX, four case reports were published, including one from this laboratory indicating that low-level gene amplification occurs in tumor cells from patients treated with MTX."'I4 This is consistent with the expectation that a low level of amplification would be sufficient to cause clinical resistance to this However, questions regarding the frequency with which this event occurs in either untreated or treated patients with malignancy have not been adequately addressed.
Although dihydrofolate reductase (DHFR) gene amplification is a common mechanism of resistance to methotrexate (MTX) in tumor cell lines, with the exception of a few case reports, the incidence of this phenomenon as a mechanism of MTX resistance in the clinic has not been reported. We studied 38 untreated patients and 29 patients in relapse with acute lymphoblastic leukemia (ALL) for gene amplification and p53 gene mutations. Three patients were studied both at diagnosis and at each of two relapses after treatment with MTX. Nine of 29 relapsed patients (31%) had low-level EVELOPMENT OF resistance to methotrexate (MTX) occurs frequently in cancer patients.' Despite the importance of MTX resistance, relatively little is known of the mechanisms underlying resistance to MTX in the clinic. MTX is a key drug in the curative regimens for acute lymphoblastic leukemia (ALL) and is extensively used for maintenance therapy. However, despite a 90% to 100% complete remission rate, most centers still report relapses in 30% to 40% of patients, and, thus, ALL is an ideal disease in which to examine the mechanisms of acquired MTX resistance? Phenotypic and genetic alterations associated with resistance to MTX have been extensively studied in experimental systems. These have included both quantitative and qualitative alterations at the level of membrane transport, intracellular polyglutamylation, and the primary intracellular target, dihydrofolate reductase MTX is a tight-binding inhibitor of the enzyme DHFR, and the concentration of MTX required to achieve inhibition of enzyme activity increases in direct proportion to the amount of the enzyme in the target cells!.' It is now well established that an important mechanism of resistance of cells to MTX is an increase in DHFR activity due to amplification of the DHFR gene. Mouse, hamster, and human MTXresistant cell lines have been described with increased levels of DHFR activity due to gene amplification.*-" After reports indicating that gene amplification is a common mechanism of resistance in cell lines exposed to gradually increasing doses of MTX, four case reports were published, including one from this laboratory indicating that low-level gene amplification occurs in tumor cells from patients treated with MTX."'I4 This is consistent with the expectation that a low level of amplification would be sufficient to cause clinical resistance to this However, questions regarding the frequency with which this event occurs in either untreated or treated patients with malignancy have not been adequately addressed.
In this report, we show that DHFR gene amplification is an important cause of MTX resistance and is associated with p53 gene mutations in blast samples from ALL patients clinically resistant to this drug. were studied. Three patients were studied at diagnosis and at each of two subsequent relapses. Two milliliters of bone marrow aspirate or 10 mL of peripheral blood in preservative-free heparin was drawn after obtaining informed written consent. Mononuclear cells were recovered from blood and bone marrow by Ficoll-Hypaque density centrifugation. Cells were washed twice with phosphate-buffered saline and stored as a pellet (-70°C). All leukemia patients studied had greater than 80% blasts after Ficoll separation. Peripheral blood mononuclear cells from 24 healthy adult volunteer donors were also studied.
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MATERIALS AND METHODS
Patient
Celt lines and culture. The human T-cell lymphoblastic leukemia cell line CCRF-CEM and the fivefold DHFR gene-amplified resistant subline CCRF-CEM/R,l5 were grown in RF'MI-1640 media supplemented with 10% horse serum.
DNA and RNA isolation. High-molecular-weight DNA was isolated from 40 X lo6 cells using the Manual DNA Extraction Kit (Applied Biosystems, Foster City, CA) according to the manufacturer's recommendations. Total cellular RNA was isolated with RNAzol (Biotecx, Houston, TX) according to the manufacturer's instructions. After isolation, DNA and RNA were quantitated by determining the A2m/Azso absorbance ratios.
DNA dot blot analysis. Dot blots were prepared using a 48-well Bio-Dot SF manifold and microfiltration apparatus (Bio-Rad, Richmond, CA) and Nytran nylon membranes (Schleicher & Schuell, Keene, NH) according to the manufacturers' directions. Briefly, 200-pL aliquots containing 5 pg DNA were denatured by 0.3 N NaOH, neutralized by 2 mol& ammonium acetate, and then individually spotted on the membrane. DNAs were fixed to the membrane by UV crosslinking with U.V. Stratalinker 1800 (Stratagene, La Jolla, CA). The dot blots were prehybridized. hybridized, and washed according to a standard protocol." Hybridization was with a human DHFR cDNA probe (pKT7-HDR). Probes were labeled with [o-"P]-deoxycytidine triphosphate (dCTP, 10 mCi/mL; DuPont CO, Wilmington, DE) to a specific activity of 10' c p d p g using a random-primed DNA labeling kit (Boehringer-Mannheim, Indianapolis, IN). After washing, damp membranes were enclosed in a single layer of plastic wrap to keep them moist, and the radioactivity was quantitated using a Betascope 603 Blot Analyzer (Betagen Corp. Waltham, MA). Autoradiography was later performed by overnight exposure to Kodak XAR-5 film (Eastman-Kodak. Rochester, NY) with intensifying screens at -70°C. Dot blots were stripped by boiling in 0. I X saline sodium citrate (SSC) and 0.1% (wt/vol) sodium dodecyl sulfate (SDS) for 15 minutes. The Betascope was used to determine if complete removal of the probe had been achieved by quantitating the amount of the residual radioactivity present on the filter. Dot blots were then reprobed with a labeled human f12-microglobulin cDNA probe as an internal control for DNA loading, and the hybridization signals were analyzed as described above.
Standard curves for dot blot analysis were prepared by varying the ratios of DNA from CCRF-CEM parental and CCRF-CEM/Rl lines, representing copy numbers 5.4.3.2, 1 S, and 1. Amplification was determined by the ratio of DHFR counts to f12-microglobulin counts and from the standard curve (Fig 1) .
Southern blot analysis. Restriction endonuclease, EcoRI, , was purchased from Boehringer Mannheim. After a 16-hour incubation, 10 pg of digested DNA was electrophoresed on 0.8% agarose gel in Tris-acetate-EDTA buffer. After depurination and neutralization, DNA samples were transferred to Nytran nylon membranes according to procedures developed by Southern" with modifications suggested by the manufacturer (Schleicher & Schuell). DNA was fixed to the filter by W crosslinking, and then prehybridization, hybridization, washing, and autoradiography steps were performed as described for the dot blot assay.
Northern blot analysis. After denaturation in MOPS-formaldehyde-formamide solution at 65°C for 15 minutes, RNA samples were electrophoresed on a 1% agarose gel with denaturant conditions. After washing the gel with IOX SSC for 30 minutes at room temperature, RNA samples were transferred to a MagnaGraph Nylon Membrane (MSI, Westboro, MA) according to a standard protoc01.'~ Fixation, prehybridization. hybridization. washing, and autoradiography steps were the same as described above.
DHFR enzyme activity assay. Blast extract preparation and DHFR assays were performed using procedures described by this laboratory." Briefly, approximately 0.5 X IOR to 3 X IOR cells (either fresh or rapidly thawed from -80°C) were resuspended in 50 mmoV L sodium phosphate buffer, pH 7.0, containing 5% glycerol, 2 mmoV L dithiothreitol (DTT), 500 KIU/mL aprotinin. I pg/mL pepstatin, and 1 pg/mL leupeptin and were then lysed by 6-second sonification bursts five times (Vibracell sonicator; Sonics and Materials Inc, Danbury, CT). Suspensions were centrifuged at 100,OOOg for 30 minutes, and the resulting supernatant was recovered for immediate analysis by a standard spectrophotometric assay. The MATS buffer system was used in assays (37°C). and final cuvette concentrations of nicotinamide adenine dinucleotide phosphate (NADPH) and H2folate were 100 pmol/L and 50 pmoVL, respectively. The rate of absorbance change in the absence of H2folate was used as background value, as it presumably incorporates any endogenous NADPH oxidizing activity of the crude blast extracts. Activity rates were determined in duplicate at least for each sample. Assays were also performed in the presence of MTX as described" to identify samples with decreased binding affinity to MTX.
DNA single-strand conformation polymorphism (SSCP) analysis for detection of the p53 mutations. DNA SSCP analysis was performed as described by Orita et a1.2' Genomic DNA obtained from For personal use only. on October 23, 2017. by guest www.bloodjournal.org From the blasts of patients was amplified using polymerase chain reaction (PCR) to double-stranded 32P-dCTP-labeled DNA using oligonucleotide primers?' The amplified regions cover exons 5 through 9, encompassing domains of the p53 gene that are highly conserved among species and the sites of frequent mutations in ALL blasts?2 The PCR mixture contained 10 pm01 of each oligonucleotide primer, 2 nmol of each of the four deoxyoligonucleotides, 5 pCi of 32P-dCTP, 50 ng of genomic DNA, and 0.125 U Taq DNA polymerase in 10 pL of the buffer specified in the Gene-Amp Kit (Perkin-Elmer Cetus, Norwalk, CT). Forty cycles of the PCRs at 94", 55", and 72°C for 30, 30, and 60 seconds, respectively, were run in Gene-Amp PCR System 9600 (Perkin-Elmer Cetus). The products were diluted 50 times with 98% formamide, 20 mmoVL EDTA, 0.05% bromophenol blue, and 0.5% xylene cyanol; boiled for 5 minutes; and then quickly chilled on ice for 10 minutes. Volumes of 5 pL were applied to acrylamide gels (6% T, acrylamide: N,N'-bisacrylamide, 49:l) containing 90 mmol/L Tris-borate, pH 8.3, 4 mmoVL EDTA, and 5% glycerol. Electrophoresis was performed at 4°C using a constant power setting of 30 W for the appropriate times. Gels were later dried on Whatman 3M paper and then exposed to Kodak XAR film (Eastman-Kodak, Rochester, NY) for 4 to 6 hours at -70°C.
Direct sequencing. All samples with putative p53 mutations detected by DNA SSCP were sequenced using The SequiTherm Cycle Sequencing Kit (Epicentre Technologies, Madison, WI), according to the manufacturer's recommendations and using oligonucleotide primers previously defined?'
RESULTS
The clinical characteristics and phenotype and karyotype analyses of leukemia patients studied are summarized in Table 1 . Both adults and children with ALL were studied. It was possible to study three patients in detail before treatment and after each of two relapses (patients 1, 24, and 32). The treatment protocols for relapsed patients are protocols used at Memorial Sloan-Kettering Hospital [New York, NY); all of the relapsed patients were treated with regimens containing MTX (NY I1 or CCG-106 for children and ALL-1 or L-20 for a d~l t s ) .~~-*~ To accurately quantitate gene copy numbers at the lowest level of detection, we standardized a dot blot assay using DNA from mononuclear cells obtained from peripheral blood of 24 healthy volunteers, using betascope counting after probing with a human DHFR cDNA as described in (Fig 2A) , giving a normal distribution (mean 5 SD, 1.0 5 0.1). Southern analysis of 10 of these samples confirmed that all were normal without evidence of gene amplification (data not shown). Based on these data and use of a standard curve developed for low-level (one to five copies) DHFR gene amplification (Fig l) , we assayed 38 blast samples from patients with untreated ALL and 34 samples from patients with relapsed ALL (three patients were studied both at diagnosis and after relapse) for evidence of gene amplification. All samples assayed contained greater than 80% blasts. To determine if gene amplification was associated with an increase in DHFR mRNA and protein, Northern analysis and DHFR activity measurements in the absence and presence of MTX were also performed when sufficient material was available. Complete analysis required at least 2 X IO' blasts (5 X lo6 for dot and Southern blotting and DNA SSCP analysis, 5 X lo6 for Northern analysis, and lo7 for DHFR enzyme activity), an amount not always possible to obtain from a bone marrow aspirate.
By establishing an upper limit of 1.5 for a normal gene copy number, we considered values of 1.6 to 2.5 to indicate twofold DHFR gene amplification, if it could also be confirmed by Southern analysis. Surprisingly, 4 of 38 blast samples from patients at diagnosis had values of greater than treated patients without gene amplification, 1,122 ? 736, n = 9). We were able to obtain a successful karyotypic analysis for only one of these patients, and the karyotype of this patient (patient 7) while abnormal, did not have any duplication of the 5q chromosome, the location of DHFR gene (Tables 1 and 2) .
Using the same criteria, blasts from 9 of 29 patients who relapsed after treatment with an antileukemia regimen containing MTX had evidence of gene amplification (Fig 2C) . Measurements of DHFR gene copy numbers ranged from 1.7-to 4.0-fold, and Southern analysis confirmed low-level gene amplification in all of these samples (twofold to fourfold; Fig 4) . Sufficient material was available for Northern analysis in eight of these patients, and all showed an increase in DHFR mRNA levels. It was possible to measure DHFR enzyme activity in four of these samples; all had elevated levels with evidence of decreased binding to MTX (Table 2 and Fig 5) . Three patients were studied before and after each of two relapses after MTX-containing chemotherapy (Table 3 ). All three patients had a normal gene copy number at diagnosis; after the first relapse, patient 1 had a 2.4-fold increase in DHFR gene copy number, associated with an approximately threefold increase in DHFR mRNA. After the second relapse, the DHFR gene copy number increased to 4, with a IO-fold increase in mRNA and a marked increase in DHFR enzyme activity. Patients 24 and 32 showed increases in DHFR gene copies only after the second relapse; these results were confirmed by Southern (Fig 4) and by Northern analysis (Fig 5) . p53 mutations. Inasmuch as mutations in the p53 gene may predispose cells to develop drug resistance due to gene amplificati~n,~~~" we analyzed all of the blast samples by DNA SSCP (exons 5 through 9) for p53 mutations. Three of 38 blast samples (patients I, 24, and 32) were found to have p53 mutations at diagnosis, but without DHFR gene amplification (Table 3) . After treatment and development of MTX resistance, all three of these patients had DHFR gene amplification. The mutations in exon 9 of the p53 gene at diagnosis persisted at each relapse (Table 3 and Figs 6 and  7) . Furthermore, blasts from four of the other six patients with low-level DHFR gene amplification at relapse had a p53 gene mutation in exon 9. Therefore, seven of the nine patients with DHFR gene amplification at relapse had mutations in the p53 gene ( Table 2) . Four of 22 blast samples from relapsed patients without DHFR gene amplification had a p53 mutation (patients 45, 47, 48, and 53; Table 2) ( P < .001). None of the blast samples studied with p53 mutations had deletions of chromosome 17p, the location of the p53 gene, by karyotypic analysis. All of the mutations observed were heterozygous.
DISCUSSION
The two most common mechanisms of resistance to MTX observed both in vitro and in vivo for experimental tumor systems are DHFR gene amplification and decreased influx of MTX.',3-7 Previously, we observed that decreased influx of MTX is associated with acquired resistance to this drug in almost half of the blast samples from patients with relapsed ALL." In the present study, we also noted that 15 of 30 relapsed blast samples studied had evidence of impaired influx (E.G., unpublished observations, 1994). We now report that DHFR gene amplification occurs in approximately 30% of blast samples from patients with ALL clinically resistant to this drug; thus, in more than half of the patients clinically resistant to MTX, these mechanisms may explain resistance. As this amplification was expected to be low-level, it was essential to determine the limits and sensitivity of the DNA dot blot assay and to confirm dot blot evidence of genomic amplification by Southern and Northern analysis. Further evidence to support the presence of DHFR gene amplification was obtained by measuring the enzyme activity of the gene product when sample quantity was sufficient. It is of interest to note that the patient with the highest level of gene amplification detected (patient 1 at second relapse, four copies) also had the highest levels of DHFR mRNA and Table 1) . Welapse number when studied. DHFR gene copy numbers calculated for these patients and normal samples are 1.8, 1.4, 4, 1.7, 1.9, and l , respectively (Table 2) .
DI-FR activity (increased 10-fold over normals). MTX binding to DHFR was not impaired in these samples, and there was no evidence of mutations in DI-FR cDNA in seven patient samples sequenced (data not shown). A cell line established from this patient (preB-cell ALL) also has a similar level of gene amplification (fourfold) and overexpression of DHFR and is 10-fold resistant to Studies by Livingstone et aIz6 and Yin et a1" showed that cell lines lacking wild-type p53 had increased frequency of gene amplification (CAD gene) on exposure to an antimetabolite (PALA). In view of these findings, we also analyzed patient samples to determine the frequency of p53 mutations associated with DHFR gene amplification. Seven of the nine samples from clinically resistant leukemia patients with DHFR gene amplification contained mutations in the p53 gene. Four blast samples from relapsed patients without detected DHFR gene amplification had p53 mutations ( Table  2) . Of interest is the occasional occurrence of low-level DHFR gene amplification in untreated patients without evidence of p53 mutations. We have previously also reported this occurrence in soft tissue sarcomas from untreated patients?" The cause of this occasional low-level amplification in tumor cells and its importance are not clear. The present study confirms previous reports that the incidence of p53 mutations in untreated patients with ALL is low. In a large series, p53 mutations were detected in only 8 of 330 cases (2%); however, possible mutations in exon 9 were not tested." In this study, only 3 of the untreated 38 patients studied had mutations in the p53 gene, and each of these three had mutations in exon 9 that persisted at relapse when DHFR gene amplification occurred. Eight other patient samples had p53 mutations at relapse; these mutations occurred in exons 5, 6, and 9. As these patients were not studied at presentation, it is not certain if the mutations developed after treatment, as has been described in lymphomas. 32 The majority of the p53 mutations found in this series were in exon 9 (7 of 11); most were transversions, and all were heterozygous. This heterozygosity could be due to the presence of normal leukocytes in the leukemic cell population studied or, possibly, due to two populations of leukemic cells: one without a mutation and the other, a mutant p53 homozygous population. The former possibility is unlikely, as most of the blast cell populations studied had greater than 80% leukemia cells. In addition, the cell line established 
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from patient 1, consisting of only leukemia cells, also had both wild-type and mutated p53 alleles on DNA sequencing (A.K. and E.G., unpublished observation, 1994). The p53 mutations in exons 5 and 6 are in the regions of previously described hot spots for mutations in this gene.." The mutations in exon 9 are also of interest in that they also occurred in evolutionary conserved domains,"' either in the nuclear localization sequence (codons 322, 325) or in the oligomerization sequence (codons 305, 307, 308, 310). Although the sample size is small, it is of interest that the three patients with p53 mutations at presentation all relapsed and died within a year after diagnosis. In addition, the other eight patients studied at relapse with p53 mutations have also subsequently died of their disease (median survival, 17 months after diagnosis v 60 months for relapse patients without p53 mutations). Larger numbers of patients must be studied to determine if p53 mutations are an independent adverse risk factor in ALL.
This study provides evidence that, in addition to decreased uptake of MTX,28 low-level gene amplification of DHFR, while less common, is a significant cause of acquired resis-
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For personal use only. on October 23, 2017. by guest www.bloodjournal.org From tance to MTX in patients with ALL. In addition, amplification is associated with the presence of a mutated p53 gene, consistent with the concept that the loss of wild-type p53 function results in loss of the checkpoint at the G I s bounda r y 2 6 , 2 7 and permits cells to enter S phase without repair of DNA, which in turn could lead to amplifications (rearrangements) and aneuploidy.'
